Loading...

Aduro BioTech

DB:290
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
290
DB
$283M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body’s natural immune system for the treatment of patients with challenging diseases. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
  • Aduro BioTech has significant price volatility in the past 3 months.
290 Share Price and Events
7 Day Returns
6.1%
DB:290
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-45.6%
DB:290
-5.6%
DE Biotechs
-4.5%
DE Market
290 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aduro BioTech (290) 6.1% -6.2% 39.4% -45.6% -73.5% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 290 underperformed the Biotechs industry which returned -5.6% over the past year.
  • 290 underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
290
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Aduro BioTech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aduro BioTech. This is due to cash flow or dividend data being unavailable. The share price is €3.1505.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aduro BioTech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aduro BioTech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:290 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.21
NasdaqGS:ADRO Share Price ** NasdaqGS (2019-04-25) in USD $3.55
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aduro BioTech.

DB:290 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ADRO Share Price ÷ EPS (both in USD)

= 3.55 ÷ -1.21

-2.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aduro BioTech is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aduro BioTech is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aduro BioTech's expected growth come at a high price?
Raw Data
DB:290 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
23.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aduro BioTech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aduro BioTech's assets?
Raw Data
DB:290 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.70
NasdaqGS:ADRO Share Price * NasdaqGS (2019-04-25) in USD $3.55
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:290 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ADRO Share Price ÷ Book Value per Share (both in USD)

= 3.55 ÷ 1.70

2.09x

* Primary Listing of Aduro BioTech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aduro BioTech is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aduro BioTech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aduro BioTech has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aduro BioTech expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aduro BioTech expected to grow at an attractive rate?
  • Aduro BioTech's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Aduro BioTech's earnings growth is expected to exceed the Germany market average.
  • Aduro BioTech's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:290 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:290 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 23.8%
DB:290 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 47.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:290 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:290 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 194 69 5 3
2022-12-31 69 -86 -60 4
2021-12-31 27 -1 -71 3
2020-12-31 20 -63 -87 5
2019-12-31 17 -22 -62 5
DB:290 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 15 -69 -95
2018-09-30 16 -92 -95
2018-06-30 17 -90 -97
2018-03-31 20 -87 -92
2017-12-31 17 -89 -92
2017-09-30 17 -90 -95
2017-06-30 17 -104 -106
2017-03-31 50 -86 -84
2016-12-31 51 -86 -91
2016-09-30 81 -63 -58
2016-06-30 97 -45 -23
2016-03-31 67 140 -51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aduro BioTech's earnings are expected to grow significantly at over 20% yearly.
  • Aduro BioTech's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:290 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Aduro BioTech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:290 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.05 0.35 -0.26 4.00
2022-12-31 -1.07 -0.65 -1.86 3.00
2021-12-31 -0.80 -0.37 -1.15 5.00
2020-12-31 -1.06 -0.92 -1.22 5.00
2019-12-31 -0.77 -0.19 -1.13 6.00
DB:290 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.21
2018-09-30 -1.22
2018-06-30 -1.25
2018-03-31 -1.22
2017-12-31 -1.26
2017-09-30 -1.35
2017-06-30 -1.56
2017-03-31 -1.27
2016-12-31 -1.40
2016-09-30 -0.91
2016-06-30 -0.36
2016-03-31 -0.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aduro BioTech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aduro BioTech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aduro BioTech has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aduro BioTech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aduro BioTech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aduro BioTech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aduro BioTech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aduro BioTech's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aduro BioTech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aduro BioTech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:290 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 15.09 -95.36 36.04
2018-09-30 16.09 -95.17 35.79
2018-06-30 16.82 -96.54 35.10
2018-03-31 20.09 -91.55 34.52
2017-12-31 17.24 -91.86 33.75
2017-09-30 17.36 -95.30 33.00
2017-06-30 17.36 -105.83 33.10
2017-03-31 50.42 -84.13 33.56
2016-12-31 50.68 -91.15 34.28
2016-09-30 81.18 -58.48 34.49
2016-06-30 96.53 -22.86 32.84
2016-03-31 67.44 -51.42 30.02
2015-12-31 72.98 -39.21 27.23
2015-09-30 48.50 -43.23 22.50
2015-06-30 31.84 -48.48 17.57
2015-03-31 22.94 -25.85 13.82
2014-12-31 13.39 -17.01 8.99
2014-09-30 3.78 -21.34 6.70
2013-12-31 0.83 -16.05 4.68
2012-12-31 0.29 -9.22 2.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aduro BioTech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aduro BioTech has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aduro BioTech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aduro BioTech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aduro BioTech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aduro BioTech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aduro BioTech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aduro BioTech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aduro BioTech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aduro BioTech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aduro BioTech has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aduro BioTech Company Filings, last reported 3 months ago.

DB:290 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 135.31 0.00 266.44
2018-09-30 157.70 0.00 265.79
2018-06-30 176.43 0.00 289.11
2018-03-31 196.96 0.00 307.31
2017-12-31 237.47 0.00 326.10
2017-09-30 256.41 0.00 345.51
2017-06-30 257.74 0.00 377.24
2017-03-31 229.02 0.00 353.96
2016-12-31 227.22 0.00 347.43
2016-09-30 249.94 0.00 369.97
2016-06-30 245.94 0.00 393.35
2016-03-31 240.28 0.00 401.98
2015-12-31 261.62 0.00 415.65
2015-09-30 243.22 0.00 445.95
2015-06-30 240.69 0.00 465.87
2015-03-31 88.81 0.00 132.98
2014-12-31 78.77 0.00 119.46
2014-09-30 24.07 1.02 39.55
2013-12-31 -6.46 12.99 8.53
2012-12-31 -3.94 5.70 3.70
  • Aduro BioTech has no debt.
  • Aduro BioTech currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aduro BioTech has sufficient cash runway for more than 3 years based on current free cash flow.
  • Aduro BioTech has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 57.5% each year.
X
Financial health checks
We assess Aduro BioTech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aduro BioTech has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aduro BioTech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aduro BioTech dividends. Estimated to be 0% next year.
If you bought €2,000 of Aduro BioTech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aduro BioTech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aduro BioTech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:290 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:290 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aduro BioTech has not reported any payouts.
  • Unable to verify if Aduro BioTech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aduro BioTech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aduro BioTech has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Aduro BioTech's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Aduro BioTech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aduro BioTech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aduro BioTech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aduro BioTech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Isaacs
COMPENSATION $3,443,244
AGE 69
TENURE AS CEO 11.3 years
CEO Bio

Mr. Stephen T. Isaacs has been the Chairman, Chief Executive Officer and President of Aduro BioTech, Inc. since 2008. Mr. Isaacs was the founder of Cerus Corporation and served as its President and Chief Executive Officer from September 1991 to May 10, 2004. While at Cerus, he led financings and partnerships providing over $250 million and negotiated major contracts with Baxter Healthcare Inc., the Consortium for Plasma Science, Kirin Pharmaceuticals and the Medimmune Corporation. Mr. Isaacs also led the Cerus initial public offering in 1997. Prior to Cerus, Mr. Isaacs served as the President and Chief Executive Officer of HRI Research from 1983 to 1991 and HRI Associates from 1979 to 1983.He has been a Director of Aduro BioTech, Inc. since 2008. He served as Director of Cerus Corporation from September 1991 to May 10, 2004. He held a research position in the Department of Chemistry at the University of California at Berkeley from 1975 to 1986. He has authored 20 scientific publications and holds 42 patents. Mr. Isaacs received his undergraduate degree in Biochemistry from University of California at Berkeley in 1973.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aduro BioTech management team in years:

1.6
Average Tenure
52
Average Age
  • The average tenure for the Aduro BioTech management team is less than 2 years, this suggests a new team.
Management Team

Steve Isaacs

TITLE
Chairman
COMPENSATION
$3M
AGE
69
TENURE
11.3 yrs

Andrea van Elsas

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
51
TENURE
1.6 yrs

Blaine Templeman

TITLE
Chief Administrative Officer & Chief Legal Officer
COMPENSATION
$2M
AGE
52
TENURE
0.3 yrs

Jennifer Lew

TITLE
Chief Financial Officer
AGE
45
TENURE
4.3 yrs

Alexandra Santos

TITLE
Executive Director of Corporate Affairs & Investor Relations

Peter Lauer

TITLE
Head of Molecular Biology

Daniel Hoth

TITLE
Acting Chief Medical Officer
AGE
72
TENURE
0.3 yrs

Dimitry Nuyten

TITLE
Chief Medical Officer

Celeste Ferber

TITLE
Senior VP
AGE
42
TENURE
0.3 yrs

Tom Dubensky

TITLE
Consultant
COMPENSATION
$2M
AGE
60
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Aduro BioTech board of directors in years:

6.5
Average Tenure
64
Average Age
  • The tenure for the Aduro BioTech board of directors is about average.
Board of Directors

Steve Isaacs

TITLE
Chairman
COMPENSATION
$3M
AGE
69
TENURE
11.3 yrs

Obi Greenman

TITLE
Director
COMPENSATION
$139K
AGE
51
TENURE
9.3 yrs

Drew Pardoll

TITLE
Chairman of Scientific Advisory Board

Stephanie O’Brien

TITLE
Lead Independent Director
COMPENSATION
$163K
AGE
60

R. Haghighat

TITLE
Director
COMPENSATION
$133K
AGE
54
TENURE
10.3 yrs

Frank McCormick

TITLE
Member of Scientific Advisory Board
COMPENSATION
$134K
AGE
68

John Mekalanos

TITLE
Member of Scientific Advisory Board

Steve Sherwin

TITLE
Director
COMPENSATION
$255K
AGE
69
TENURE
3.8 yrs

Tom Gajewski

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Darren Higgins

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • Aduro BioTech insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Feb 19 Sell Andrea van Elsas Individual 26. Feb 19 26. Feb 19 -6,844 €3.74 €-25,620
14. Dec 18 Sell Andrea van Elsas Individual 12. Dec 18 12. Dec 18 -2,171 €2.58 €-5,603
14. Dec 18 Sell Jennifer Lew Individual 12. Dec 18 12. Dec 18 -1,035 €2.58 €-2,671
14. Dec 18 Sell Stephen Isaacs Individual 12. Dec 18 12. Dec 18 -5,829 €2.58 €-15,045
14. Dec 18 Sell Blaine Templeman Individual 12. Dec 18 12. Dec 18 -1,241 €2.58 €-3,203
14. Sep 18 Sell Stephen Isaacs Individual 13. Sep 18 13. Sep 18 -24,143 €5.57 €-134,364
14. Sep 18 Sell Blaine Templeman Individual 13. Sep 18 13. Sep 18 -6,056 €5.57 €-33,704
14. Sep 18 Sell Andrea van Elsas Individual 13. Sep 18 13. Sep 18 -9,754 €5.57 €-54,284
14. Sep 18 Sell Jennifer Lew Individual 13. Sep 18 13. Sep 18 -5,623 €5.57 €-31,294
14. Sep 18 Sell Natalie Sacks Individual 13. Sep 18 13. Sep 18 -3,028 €5.57 €-16,852
06. Sep 18 Sell Natalie Sacks Individual 04. Sep 18 04. Sep 18 -4,504 €6.17 €-27,782
X
Management checks
We assess Aduro BioTech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aduro BioTech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body’s natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

Details
Name: Aduro BioTech, Inc.
290
Exchange: DB
Founded: 2000
$254,503,639
79,852,045
Website: http://www.aduro.com
Address: Aduro BioTech, Inc.
740 Heinz Avenue,
Berkeley,
California, 94710,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ADRO Common Stock Nasdaq Global Select US USD 16. Apr 2015
DB 290 Common Stock Deutsche Boerse AG DE EUR 16. Apr 2015
Number of employees
Current staff
Staff numbers
152
Aduro BioTech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:38
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.